Traffic jam in the cell
A German-Polish team with scientists from Freiburg revealed how cells survive mistargeting of mitochondrial proteins
Mitochondria need more than a thousand proteins to fulfill their multitude of functions. The majority of mitochondrial proteins are synthesized in the cytosol, the intracellular fluid, and need to be transported into the mitochondria. Defects in the protein import machinery lead to mitochondrial dysfunctions and the accumulation of mitochondrial precursor proteins in the cytosol.
How the cell reacts to the resulting stress has been unknown so far. To address this question, Dr. Silke Oeljeklaus and Dr. Sebastian Wiese from the Warscheid group investigated, with the help of high resolution mass spectrometry, how the proteome of cells with a defect in the mitochondrial protein import is altered. The proteome of a cell comprises all proteins that are present in the cell at a given point of time. Based on these data, the research team discovered that UPRam consists of two main pathways that are used by the cell to protect itself against a defective mitochondrial protein import. First, the cell inhibits translation, to counteract further accumulation of mitochondrial precursor proteins. Second, the cell activates the proteasome, which removes the already existing traffic jam on the mitochondrial import pathway.
In order to provide proof for UPRam, the scientists decoupled the activation of the proteasome from translational inhibition by the use of artificially mistargeted mitochondrial proteins. They showed that the cell maintains its inner balance as it adjusts the mechanisms for the regulation of the cellular protein homeostasis to the state of its mitochondria. The cell activates the proteasome by a more efficient assembly and, thus, reacts directly to the amount of proteins that fail to be imported into the mitochondria
Original publication
Most read news
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.